Patient characteristics according to donor lymphocyte infusion regimen used
| Features . | Bulk (n = 28) . | Escalating (n = 20) . | Overall (n = 48) . |
|---|---|---|---|
| Donor type | |||
| SIB/VUD | 18/10 | 10/10 | 28/20 |
| Patient gender: | |||
| Male/female | 8/20 | 16/4 | 24/24 |
| GVHD prophylaxis at SCT: | |||
| TCD/T-replete | 18/10 | 12/8 | 30/18 |
| GVHD after SCT: | |||
| Grade 2-4 acute | 10 | 7 | 17 |
| Extensive chronic | 10 | 2 | 12 |
| Relapse | |||
| Cytogenetic alone | 7 | 9 | 16 |
| Hematologic-CP | 17 | 6 | 23 |
| Hematologic-AP | 4 | 5 | 9 |
| Interval SCT → relapse | 16.6 | 12.2 | 12.5 |
| Months (range) | 3-103 | 4-51 | 3-103 |
| Interval relapse → DLI | 10.9 | 12.9 | 11.1 |
| Months (range) | 0-70 | 1-53 | 0-70 |
| Features . | Bulk (n = 28) . | Escalating (n = 20) . | Overall (n = 48) . |
|---|---|---|---|
| Donor type | |||
| SIB/VUD | 18/10 | 10/10 | 28/20 |
| Patient gender: | |||
| Male/female | 8/20 | 16/4 | 24/24 |
| GVHD prophylaxis at SCT: | |||
| TCD/T-replete | 18/10 | 12/8 | 30/18 |
| GVHD after SCT: | |||
| Grade 2-4 acute | 10 | 7 | 17 |
| Extensive chronic | 10 | 2 | 12 |
| Relapse | |||
| Cytogenetic alone | 7 | 9 | 16 |
| Hematologic-CP | 17 | 6 | 23 |
| Hematologic-AP | 4 | 5 | 9 |
| Interval SCT → relapse | 16.6 | 12.2 | 12.5 |
| Months (range) | 3-103 | 4-51 | 3-103 |
| Interval relapse → DLI | 10.9 | 12.9 | 11.1 |
| Months (range) | 0-70 | 1-53 | 0-70 |
SIB, sibling donor; VUD, volunteer unrelated donor; SCT, stem cell transplant; GVHD, graft-versus-host disease; TCD, T-cell depleted SCT; hematologic-CP, chronic phase; hematologic-AP, hematologic relapse in advanced phase.